Cite
HARVARD Citation
Hassel, J. et al. (n.d.). 35MO Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (TIL) cell therapy: Post hoc analysis of the C-144-01 trial of lifileucel in patients with advanced melanoma. Immuno-oncology technology. p. . [Online].